Safety and efficacy of intensity-modulated stereotactic body radiotherapy using helical tomotherapy for lung cancer and lung metastasis.
Safety and efficacy of intensity-modulated stereotactic body radiotherapy using helical tomotherapy for lung cancer and lung metastasis.
复制标题
DOI：
10.1155/2014/473173
复制
发表时间：
2014
影响因子：
--
通讯作者：
Kikuchi Y
中科院分区：
文献类型：
--
作者：
Nagai A;Shibamoto Y;Yoshida M;Inoda K;Kikuchi Y
立体定向体部放射治疗（SBRT）是一种有效的治疗肺部肿瘤的方法。然而，使用螺旋强度调制（IM）SBRT是有争议的。我们研究了使用螺旋断层放射治疗的IMSBRT治疗肺肿瘤患者的结局，日本标准分割方案为48戈伊分4次（n = 37）或改良方案为50 - 60戈伊分5 - 8次（n = 35）。患者的中位年龄为76岁，存活患者的中位随访期为20个月（范围，6 - 46）。4次组的中位PTV为6.9 cc，5 - 8次组为14 cc（P = 0.001）。4次组37例患者中有2例患者发生2级放射性肺炎，5至8次组35例患者中有2例患者发生2级放射性肺炎（对数秩P = 0.92）。未观察到其他严重并发症。4次组2年的LC率为87%，5 - 8次组为83%。螺旋IMSBRT治疗肺部肿瘤是安全有效的。具有发生严重并发症的高风险的患者也可以使用5 - 8次分割进行安全治疗。目前的研究结果保证了螺旋IMSBRT的进一步研究。
Stereotactic body radiotherapy (SBRT) proved to be an effective treatment with acceptable toxicity for lung tumors. However, the use of helical intensity-modulated (IM) SBRT is controversial. We investigated the outcome of lung tumor patients treated by IMSBRT using helical tomotherapy with a Japanese standard fractionation schedule of 48 Gy in 4 fractions (n = 37) or modified protocols of 50–60 Gy in 5–8 fractions (n = 35). Median patient's age was 76 years and median follow-up period for living patients was 20 months (range, 6–46). The median PTV was 6.9 cc in the 4-fraction group and 14 cc in the 5- to 8-fraction group (P = 0.001). Grade 2 radiation pneumonitis was seen in 2 of 37 patients in the 4-fraction group and in 2 of 35 patients in the 5- to 8-fraction group (log-rank P = 0.92). Other major complications were not observed. The LC rates at 2 years were 87% in the 4-fraction group and 83% in the 5- to 8-fraction group. Helical IMSBRT for lung tumors is safe and effective. Patients with a high risk of developing severe complications may also be safely treated using 5–8 fractions. The results of the current study warrant further studies of helical IMSBRT.
登录
查看更多内容
影响因子：
2.1
作者：
Klein M;Gaede S;Yartsev S
通讯作者：
Yartsev S
影响因子：
5.7
作者：
Borst, Gerben R.;Ishikawa, Masayori;Sonke, Jan-Jakob
通讯作者：
Sonke, Jan-Jakob
影响因子：
5.3
作者：
Nomori, H;Watanabe, K;Uno, K
通讯作者：
Uno, K
影响因子：
3.1
作者：
Hodge, Wes;Tome, Wolfgang A.;Mehta, Minesh P.
通讯作者：
Mehta, Minesh P.
DOI：
10.1016/j.ijrobp.2008.12.093
发表时间：
2009-10-01
影响因子：
7
作者：
Iwata, Hiromitsu;Shibamoto, Yuta;Ito, Masato
通讯作者：
Ito, Masato